Klin Padiatr 2025; 237(03): 117-140
DOI: 10.1055/a-2556-4302
Guideline

GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025

GPOH-Leitlinien für die Diagnose und Erstlinien-Behandlung von Patienten mit neuroblastischen Tumoren, update 2025
1   Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
,
Theresa Thole
2   Pediatric Oncology and Hematology, Charité University Hospital Berlin, Berlin, Germany
,
Sveva Castelli
2   Pediatric Oncology and Hematology, Charité University Hospital Berlin, Berlin, Germany
,
Beate Timmermann
3   Westgerman Protontherapycenter Essen, University of Duisburg-Essen, Duisburg, Germany
,
Danny Jazmati
4   Department of Radiation Oncology, Heinrich Heine University Düsseldorf, Dusseldorf, Germany
,
Rudolf Schwarz
5   Department for Radiotherapy, UKE, Hamburg, Germany
,
Jörg Fuchs
6   Pediatric Surgery and Urology, University of Tübingen, Tübingen, Germany
,
Steven Warmann
7   Department of Pediatric Surgery, Charité University Hospital Berlin, Berlin, Germany
,
Jochen Hubertus
8   Department of Pediatric Surgery, Marien-Hospital Witten, Witten, Germany
,
Matthias Schmidt
9   Nuclear Medicine, University of Cologne, Cologne, Germany
,
Julian Rogasch
10   Nuclear Medicine, Charité University Hospital Berlin, Berlin, Germany
,
Friederike Körber
11   Institut und Poliklinik für Radiologische Diagnostik, Kinderradiologie, University of Cologne, Cologne, Germany
,
Christian Vokuhl
12   Pediatric Pathology, Institute for Pathology, University of Bonn, Bonn, Germany
,
Jürgen Schäfer
13   Diagnostic and Interventional Radiology, University of Tübingen, Tübingen, Germany
,
Johannes Hubertus Schulte
14   Pediatric Oncology and Hematology, University of Tübingen, Tübingen, Germany
,
Hedwig Deubzer
2   Pediatric Oncology and Hematology, Charité University Hospital Berlin, Berlin, Germany
,
Carolina Rosswog
1   Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
15   Experimental Pediatric Oncology, University of Cologne, Cologne, Germany
,
Matthias Fischer
1   Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
15   Experimental Pediatric Oncology, University of Cologne, Cologne, Germany
,
Peter Lang
14   Pediatric Oncology and Hematology, University of Tübingen, Tübingen, Germany
,
Thorsten Langer
16   Childrens’ Hospital, University Hospital Schleswig-Holstein Lübeck Campus, Lübeck, Germany
,
Kathy Astrahantseff
2   Pediatric Oncology and Hematology, Charité University Hospital Berlin, Berlin, Germany
,
Holger Lode
17   Pediatric Oncology and Hematology, University of Greifswald, Greifswald, Germany
,
Barbara Hero
1   Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
,
Angelika Eggert
2   Pediatric Oncology and Hematology, Charité University Hospital Berlin, Berlin, Germany
› Institutsangaben
Preview

Abstract

The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Many low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise disease characterization for each patient at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.

Zusammenfassung

Der klinische Verlauf von Neuroblastomen ist sehr variabel. Bei Patienten mit günstigem Risikoprofil werden regelhaft Spontanregression der Tumoren beobachtet. Bei Hochrisiko-Neuroblastom können dagegen nur ca. 50% der Patienten durch eine intensive multimodale Therapie geheilt werden. Eine exakte Risikoklassifizierung jedes einzelnen Patienten ist von entscheidender Bedeutung eine korrekte risikoadaptierte Therapie. Die hier vorgestellten Empfehlungen berücksichtigen Ergebnisse von nationalen und internationalen klinischen Studien und definieren den gegenwärtigen Standard für die Behandlung von Patienten mit Neuroblastomen in Deutschland außerhalb von klinischen Studien.



Publikationsverlauf

Artikel online veröffentlicht:
09. Mai 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany